Pharmaceutical Contract Manufacturing Market Growth

Global Pharmaceutical Contract Manufacturing Market Growth is Anticipated at a CAGR of 4.5%; Market Value to be USD 155.4 Billion by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, given the increased approvals of small molecule drugs, growing complexity of drug synthesis and need for reducing time-to-market, the pharmaceutical contract manufacturing market is well positioned for future growth.

Global Pharmaceutical Contract Manufacturing Market Overview

The global pharmaceutical contract manufacturing market is expected to reach USD 155.4 million by 2035, growing at a CAGR of 4.5% during the forecast period till 2035.

The emergence of novel therapeutic modalities has increased the complexity of pharmaceutical development and manufacturing, making it challenging for many companies to manage these operations independently. Due to this, pharmaceutical companies encounter many difficulties in conducting development and manufacturing operations independently. This has prompted many small and large pharmaceutical companies to outsource their manufacturing operations to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). Further, outsourcing enables developers to access specialized expertise, optimize production workflows, ensure regulatory compliance, and consistent product quality. In order to adapt to these shifting dynamics and address the need of rapidly changing industry, the demand for tailored, advanced contract manufacturing solutions is expected to rise over the forecast period.

Browse ~155 figures and ~205 market data tables spread across ~460 pages and detailed Table of Content on “Global Pharmaceutical Contract Manufacturing Market, till 2035 by Type of Product Manufactured (API & Intermediates, and FDF), Type of API (Originator API and Generic API), API Potency (Low Potent API and High Potent API), Type of FDF (Originator FDF and Generic FDF), Dosage Form (Oral Solids, Liquids, Emulsions and Other Dosage Forms), Type of Oral Solid (Tablets, Capsules and Other Oral Solids), Type of Packaging Offered (Bottles, Blister Packs, Vials, Prefilled Syringes, Cartridges, Ampoules, Oral Liquid Bottles and Other Types of Packaging), Scale of Operation (Clinical Scale and Commercial Scale), End Users (Small, Mid-sized, and Large and Very Large Companies) Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa) and Leading Players” here: https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market/191.html

Market Drivers

Several factors are propelling global pharmaceutical contract manufacturing market growth. One of the key factors driving the future of market is the presence of multiple late-stage candidates, indicating several short and mid-term opportunities for the companies engaged in this domain. Contract manufacturing organizations offer operational flexibility that allows pharmaceutical companies to meet growing drug demand by streamlining production across different scales and managing unexpected challenges more efficiently. Owing to these benefits, more companies are anticipated to shift towards outsourcing pharmaceutical manufacturing, leading to a significant increase in the market growth.

Market Restraints

While the global pharmaceutical contract manufacturing market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. One of the primary challenges is stringent and evolving regulatory standards imposed by global and local regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO). Moreover, the dependency of pharmaceutical contract manufacturers on the network of raw material suppliers, API producers and specialized equipment manufacturers make them vulnerable to global supply chain disruption. These factors collectively act as barriers to wider adoption, challenging the market’s ability to sustain its growth trajectory.

Growth Factors

Despite the aforementioned restraints, several factors continue to drive the global pharmaceutical contract manufacturing market growth forward. One notable factor is the  increasing demand for one-stop shops offering end-to-end manufacturing services, making CDMOs and CMOs an attractive option. Further, the integration of artificial intelligence and machine learning in pharmaceutical manufacturing has significantly resulted in improved efficiency, quality, and agility across different processes. Owing to these factors, it can be anticipated that the global pharmaceutical contract manufacturing market will flourish remarkably in the foreseen future.

Global Pharmaceutical Contract Manufacturing Market Segments

Based on the type of product manufactured, the market is segmented into APIs and Intermediates, and FDFs.

• The APIs and intermediates sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of around 60% in the current year.
• API and intermediates sub-segment is anticipated to show the highest growth rate of 4.5%, during the forecast period.

Based on the type of API, the market is segmented into originator APIs and generic APIs.

• The originator APIs sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of more than 50% in the current year.
• The generic APIs sub-segment is anticipated to grow at an annualized rate of 5.0%, during the forecast period.

Based on the API potency, the market is segmented into low potent APIs and high potent APIs.

• The low potent APIs sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of around 85% in the current year.
• The high potent APIs sub-segment is anticipated to grow at an annualized rate of 9.0%, during the forecast period.

Based on the type of FDF, the market is segmented into originator FDFs and generic FDFs.

• The originator FDFs sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of about 55% in the current year.
• The generic FDFs sub-segment is anticipated to grow at an annualized rate of 5.3%, during the forecast period.

Based on the dosage form, the market is segmented into oral solids, liquids, emulsions and other dosage forms.

• The oral solids sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of around 55% in the current year.
• The liquids sub-segment is anticipated to grow at an annualized rate of 4.5%, during the forecast period.

Based on the type of oral solid, the market is segmented into tablets, capsules and other oral solids.

• The tablets sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing ~70% revenue share in the current year.
• The capsules sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 5.7% during the forecast period.

Based on the type of packaging offered, the market is segmented into bottles, blister packs, oral liquid bottles, vials, prefilled syringes, cartridges, ampoules and other types of packaging.

• The bottles sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing about 30% revenue share in the current year.
• The blister packs sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 5.5% during the forecast period.

Based on the scale of operation, the market is segmented into clinical scale and commercial scale.

• The commercial scale sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing about 95% of revenue share in the current year.
• The clinical scale sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 7.8% during the forecast period.

Based on the end user, the market is segmented into small companies, mid-sized companies, and large and very large companies.

• The large and very large companies sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing around 45% revenue share in the current year.
• The small companies sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 5.2% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa.

• North America dominated the global pharmaceutical contract manufacturing market and accounted for the largest revenue share (~45%) in the current year.
• In Asia-Pacific, the global pharmaceutical contract manufacturing market is anticipated to demonstrate lucrative growth of 5.2% during the forecast period.

Key Companies Profiled

The global pharmaceutical contract manufacturing market report also includes detailed profiles of key companies (listed below) that are engaged in the pharmaceutical contract manufacturing domain:

• Albemarle
• Aspen Pharmacare
• Bausch Health Sciences
• Catalent
• Delpharm
• Eurofins Scientific
• Evonik Industries
• Fareva
• Fresenius Kabi
• Intas Pharmaceuticals
• Lonza
• Micro Labs
• Nipro Patch
• Patheon
• PiSA Farmacéutica
• Recipharm
• Sandoz
• West Pharmaceutical Services
• Wockhardt
• WuXi AppTec

You Can Download Free Sample PDF Copy of This Report at:
https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 1,500 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com